AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9751323
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of prostate specific antigen values with quality of life and measurable disease responses
Trial: 7790732
Drug: Indomethacin pretreatment
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin pretreatment (50 mg suppository administered 30 min before hyperthermia)
Trial: 1722918
Drug: Org 10172
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 10172 (Lomoparan, i.v. bolus injection of 3,250 anti‐Xa units followed by 750 units twice daily s.c. for 8 days)
Trial: 1722918
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) (500 mg orally 14 and 2 h before i.v. Org 10172 administration)
Trial: 7152443
Drug: Combined low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combined low-dose uricostatic and uricosuric regimen
Trial: 25915826
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of one portion of cake fortified with barley's beta‐glucan
Trial: 25915826
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of the same cake without the enrichment (placebo)
Trial: 9854508
Drug: EET therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EET therapy (intravenous administration of IFN‐gamma or TNF‐SAM2 followed by OK‐432)
Trial: 9854508
Drug: EET therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EET therapy (more than 5 courses)
Trial: 9854508
Drug: EET therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EET therapy
Trial: 2212408
Drug: Inhaled adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled adenosine 5'-monophosphate (AMP)
Trial: 26349123
Drug: Experimental dentifrice
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental dentifrice formulations (1450 ppm fluoride) with 2% isopentane
Trial: 26349123
Drug: Experimental dentifrice
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental dentifrice formulations (1450 ppm fluoride) without 2% isopentane
Trial: 10720518
Drug: Thalidomide therapy
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide therapy
Trial: 19883313
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of T cell expansions (regardless of therapy)
Trial: 15112860
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate (10 mg i.v.)
Trial: 11552902
Drug: Ridogrel (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridogrel (5 mg/day for 12 weeks)
Trial: 9631813
Drug: Metered-dose inhaler
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered-dose inhaler (MDI) delivering 100 microg of methacholine
Trial: 7697689
Drug: Sustained-release cream
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release cream
Trial: 7697689
Drug: Standard cream
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard cream
Trial: 3666661
Drug: Verapamil (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (120 mg orally)
Trial: 31922999
Drug: Midazolam (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.04 mg·kg)
Trial: 29433481
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy plus early ACLR
Trial: 29433481
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy plus delayed ACLR
Trial: 25515553
Drug: Botanical oil
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Botanical oil (BO) combination (borage/echium oil)
Trial: 22901969
Drug: Bivalirudin (BIV)
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bivalirudin (BIV) + 2-hour infusion after PCI
Trial: 22901969
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa receptor inhibitor (GPI)
Trial: 18761239
Drug: Superficial cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superficial cervical plexus block with 0.35 mL/kg of 0.5% levobupivacaine
Trial: 18761239
Drug: Combined cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined cervical plexus block with 0.2 mL/kg of 0.5% levobupivacaine (deep) and 0.15 mL/kg (superficial)
Trial: 11821603
Drug: Ropivacaine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 200 mg dissolved in 100 ml saline
Trial: 11821603
Drug: Saline 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 100 mg
Trial: 10765864
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (n = 24): Irreversibly infected dentin was partially removed prior to the application of the bonding agent and restorative material.
Trial: 10765864
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 24): All identifiable, irreversibly infected dentin was removed prior to the application of the bonding agent and restorative material.
Trial: 7669483
Drug: Isoprenaline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoprenaline (10 min i.v. infusion of 1 microgram min-1)
Trial: 7669483
Drug: Adrenaline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline (10 min i.v. infusion of 1 microgram min-1)
Trial: 7669483
Drug: Isomazole (p.o.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomazole (p.o. administration of 40 mg)
Trial: 7669483
Drug: Meribendan (p.o.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meribendan (p.o. administration of 40 mg)
Trial: 7669483
Drug: Celiprolol (p.o.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (p.o. administration of 1200 mg)
Trial: 2285629
Drug: Nifedipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (2 x 10 mg capsules three times daily)
Trial: 2285629
Drug: Nisoldipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (2 x 10 mg tablets once daily)
Trial: 7023715
Drug: Daunorubicin (DNR)
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin (DNR) 1.5 mg/kg on day 1 + ARA‐C 2 mg/kg on days 1‐5 (R1)
Trial: 7023715
Drug: Daunorubicin (DNR)
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin (DNR) 1.5 mg/kg on days 1 and 2 + ARA‐C 2 mg/kg on days 4‐8 (R2)
Trial: 7023715
Drug: Daunorubicin-DNA complex
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin-DNA complex 1.5 mg/kg on days 1 and 2 + ARA‐C 2 mg/kg on days 4‐8 (R3)
Trial: 7023715
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with DNR-DNA complex vs free DNR
Trial: 31862174
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment group (SBP goal of <120 mmHg)
Trial: 31862174
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment group (SBP goal of <140 mmHg)
Trial: 25729623
Drug: Ciclesonide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide (200 µg)
Trial: 23816671
Drug: Pregabalin 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150 mg 2 h prior to induction of anesthesia and 75 mg twice daily for 2 post-operative days
Trial: 17426398
Drug: 1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine gel + fluoridated dentifrice
Trial: 22037722
Drug: Topical suspension
RxNorm normalized name: Topical Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical suspension of bacterial antigens (Lantigen B)
Trial: 11176083
Drug: Remifentanil (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (loading dose 1 microg/kg; maintenance infusion, 0.25 microg x kg(‐1) x min‐1)
Trial: 11176083
Drug: Alfentanil (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (loading dose, 50 microg/kg; maintenance infusion, 1 microg x kg(‐1) x min‐1)
Trial: 7996800
Drug: Active kallikrein
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active kallikrein excretion
Trial: 27237769
Drug: IM IFN
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM IFN beta‐1a 30 mcg once weekly (full-dose group)
Trial: 27237769
Drug: IM IFN
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM IFN beta‐1a 15 mcg once weekly for 2 weeks then 30 mcg once weekly (titration group)
Trial: 24508036
Drug: 100μg gE/AS01B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100μg gE/AS01B (one dose)
Trial: 24508036
Drug: 25μg gE/AS01B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25μg gE/AS01B (two doses, two months apart)
Trial: 24508036
Drug: 50μg gE/AS01B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50μg gE/AS01B (two doses, two months apart)
Trial: 24508036
Drug: 100μg gE/AS01B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100μg gE/AS01B (two doses, two months apart)
Trial: 24508036
Drug: 100μg gE/saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100μg gE/saline (two doses, two months apart)
Trial: 22730850
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein milk supplement
Trial: 22730850
Drug: Higher carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher carbohydrate supplement
Trial: 20414783
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine A 2% drops
Trial: 18498912
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of aceclofenac 100 mg
Trial: 18498912
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of aceclofenac 100 mg
Trial: 15342210
Drug: Enoxaparin 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 1.5 mg/kg subcutaneous (s.c.) once daily
Trial: 15342210
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) intravenous (i.v.) adjusted to aPTT 1.5‐2.5 times control
Trial: 11249891
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 16 mg, uptitrated to 32 mg after 4 weeks
Trial: 11249891
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg, uptitrated to 10 mg after 4 weeks
Trial: 8049846
Drug: Amiloride (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (0.3 mg/m2 body surface area)
Trial: 3352886
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (steroids preoperatively and for 4 days postoperatively)
Trial: 3352886
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (steroids pre- and postoperatively for 1 day)
Trial: 3352886
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (no steroids)
Trial: 28068207
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution activated by diode laser
Trial: 28068207
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution with methylene blue dye activated by diode laser
Trial: 28068207
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (positive control)
Trial: 25724847
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (3 mg, six 2-monthly oral doses over 1 year)
Trial: 20609398
Drug: DTaP(5)‐IPV/Hib administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP(5)‐IPV/Hib administered concurrently with PCV7
Trial: 20609398
Drug: DTaP(5)‐IPV/Hib administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP(5)‐IPV/Hib administered at separate visits (staggered group)
Trial: 16984993
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone therapy (Intrinsa)
Trial: 16984993
Drug: Oral methyltestosterone
RxNorm normalized name: Methyltestosterone
DrugBank: Methyltestosterone (DB06710)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methyltestosterone
Trial: 10671676
Drug: CAV/PE‐W (dose‐intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAV/PE‐W (dose‐intensive weekly alternating chemotherapy)
Trial: 10671676
Drug: CAV/PE (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAV/PE (standard alternating chemotherapy)
Trial: 8148854
Drug: Flurbiprofen 200
RxNorm normalized name: flurbiprofen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 200 mg sustained-release
Trial: 8148854
Drug: Ketoprofen 200
RxNorm normalized name: ketoprofen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 200 mg sustained-release
Trial: 3484547
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug change (control)
Trial: 3484547
Drug: Addition or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition or deletion of a single drug other than barbiturate
Trial: 22689417
Drug: Ranolazine (750/1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine (750/1000 mg bid)
Trial: 20938175
Drug: Antofloxacin hydrochloride
RxNorm normalized name: danofloxacin
DrugBank: Danofloxacin (DB11393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antofloxacin hydrochloride (400 mg loading dose on day 1, followed by 200 mg daily)
Trial: 20938175
Drug: Levofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (200 mg orally twice daily for 7-14 days)
Trial: 18549888
Drug: VBLOC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VBLOC therapy (intra-abdominal vagal blocking)
Trial: 18549888
Drug: VBLOC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VBLOC therapy
Trial: 9076203
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (40 mg tablet)
Trial: 22639944
Drug: Yoga intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga intervention (eight weeks of weekly teacher-led yoga class and home-based daily yoga practice delivered by DVD)
Trial: 17295995
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with incentives I
Trial: 17295995
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with incentives II
Trial: 9349928
Drug: Ticlopidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (250 mg per day)
Trial: 2879344
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen (HO) with diazepam (5 mg) in group I
Trial: 29349539
Drug: Experimental bundle
RxNorm normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental bundle with intraperitoneal lavage with antibiotic solution, fascial closure with Triclosan-coated sutures, and Mupirocin ointment application on skin staples
Trial: 25281223
Drug: MDMA (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (0.5 or 1.0 mg/kg)
Trial: 17959585
Drug: i.v. acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. acetaminophen
Trial: 11094668
Drug: Midazolam 3
RxNorm normalized name: KETAMINE HYDROCHLORIDE 25 mg / MIDAZOLAM 3 mg / HYDROXYZINE HYDROCHLORIDE 10 mg SUBLINGUAL TROCHE [MKH Dose Pack]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 3 mg administered at 1 minute prior to propofol
Trial: 11094668
Drug: Midazolam 3
RxNorm normalized name: KETAMINE HYDROCHLORIDE 25 mg / MIDAZOLAM 3 mg / HYDROXYZINE HYDROCHLORIDE 10 mg SUBLINGUAL TROCHE [MKH Dose Pack]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 3 mg administered at 2 minutes prior to propofol
Trial: 11094668
Drug: Midazolam 3
RxNorm normalized name: KETAMINE HYDROCHLORIDE 25 mg / MIDAZOLAM 3 mg / HYDROXYZINE HYDROCHLORIDE 10 mg SUBLINGUAL TROCHE [MKH Dose Pack]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 3 mg administered at 4 minutes prior to propofol
Trial: 11094668
Drug: Midazolam 3
RxNorm normalized name: KETAMINE HYDROCHLORIDE 25 mg / MIDAZOLAM 3 mg / HYDROXYZINE HYDROCHLORIDE 10 mg SUBLINGUAL TROCHE [MKH Dose Pack]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 3 mg administered at 6 minutes prior to propofol
Trial: 11094668
Drug: Midazolam 3
RxNorm normalized name: KETAMINE HYDROCHLORIDE 25 mg / MIDAZOLAM 3 mg / HYDROXYZINE HYDROCHLORIDE 10 mg SUBLINGUAL TROCHE [MKH Dose Pack]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 3 mg administered at 10 minutes prior to propofol
Trial: 31865288
Drug: Chakrayoga Meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chakrayoga Meditation Program (twice a week for 2 hours during 6 weeks, consisting of 1 hour of Chakrayoga and 1 hour of meditation)
Trial: 29079365
Drug: Continuous-flow cryocompression
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous-flow cryocompression therapy (CFCT)
Trial: 25875777
Drug: Deferoxamine mesylate
RxNorm normalized name: Deferoxamine Mesylate
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferoxamine mesylate (62 mg/kg/day, maximum dose not to exceed 6000 mg/day)
Trial: 25087476
Drug: Low-dose DENVax
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose DENVax vaccine
Trial: 25087476
Drug: High-dose DENVax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DENVax vaccine
Trial: 25087476
Drug: Placebo (low-dose)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo (low-dose)
Trial: 25087476
Drug: Placebo (high-dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (high-dose)
Trial: 18633464
Drug: Frequent Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequent Therapy (FT)
Trial: 18633464
Drug: Minimal Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal Therapy (MT)
Trial: 12135015
Drug: L‐NMMA (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA (12 mg/kg within 5 min, followed by a maintenance infusion of 6.7 mg/kg/h i.v.)
Trial: 8523851
Drug: Drug-resistant pulmonary
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-resistant pulmonary tuberculosis patients continuing chemotherapy
Trial: 8523851
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with drug-resistant tuberculosis
Trial: 8523851
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with drug-resistant pulmonary tuberculosis
Trial: 6779371
Drug: Metronidazole (600‐1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (600‐1200 mg daily)